Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Disappointing response by the market
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(46)
•••
Comment by greaterfoolFredon Jul 08, 2021 2:18pm
136 Views
Post# 33515539

RE:RE:Disappointing response by the market

RE:RE:Disappointing response by the market chrispi is right.  This matters to companies interested in MS, but what everyone else hears is that xb3 works in rodents.  Well, we knew that.  What will move us is clinical news, or at least news that xb3 works in primates.  We have to follow the long term plan; find partners and keep cash in the bank.  Our day will come.

chrispi wrote: Sometimes it takes more than 1.5 hours for people to digest the news ;) ... especially during the summer holiday season. But more importantly than the market realizing, or not, the importance and significance of this successful study, is that our current and future partners are now aware of it. That will help licensing negotiations with current and future partners!


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities